MedTrace Logo

Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)

NCT04580680 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-02-12

No results posted yet for this study

Summary

Worldwide, the use of Extracorporeal Blood Purification (EBP) in everyday clinical practice is becoming increasingly common, particularly in critical care settings. The efficacy of most of these treatments on removal of inflammatory mediators is the main rationale behind the use of EBP in critically ill patients with multiorgan dysfunction. Nonetheless, there are still some doubts as to the clinical efficacy of bacterial toxins and cytokines removal and many clinical trials aiming at exploring the effect of EBP on long-term outcomes of septic patients have failed to demonstrate consistent results regarding 28 day- or hospital-mortality rates. The primary aim of this observational prospective web-based registry is to define the possible clusters of critically ill patients - treated with extracorporeal blood purification therapies worldwide - who are homogeneous regarding both clinical and treatment characteristics and seem to benefit the most from EBP.

Conditions

Interventions

DEVICE

Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)

At each participating center, EBP treatments with commercial membranes will be delivered in accordance with local practice and local levels of expertise. Enrolled patients will not receive additional treatments other than those routinely administered in ICUs. Nonetheless, all parameters settings for EBP treatments will be recorded in the web-based registry and analyzed a posteriori to reveal potential correlations with patient outcomes.

Sponsors & Collaborators

  • University of Florence

    collaborator OTHER

  • Careggi Hospital

    lead OTHER

Principal Investigators

  • Gianluca Villa, md · University of Florence, Florence, Italy

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2025-09-30
Completion
2025-09-30
FDA Device
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04580680 on ClinicalTrials.gov